Strategic Partnership Leverage Titan's ProNeura delivery platform and existing collaborations (Braeburn for Probuphine; Ocular Therapeutix licensing) to pursue co-development or licensing deals with companies in chronic disease management, neurology, or endocrine disorders where continuous drug delivery can improve outcomes.

M&A Growth The recent merger activity creating Black Titan Corporation signals a corporate refresh and potential integration with broader medtech and pharma portfolios; target BD opportunities around ProNeura assets or related drug delivery platforms in addiction treatment, chronic itch, or other long-acting therapies.

Niche Market Focus Probuphine’s six-month sustained buprenorphine delivery demonstrates a unique value proposition for addiction treatment; explore expanded payer and clinic partnerships, pharmacovigilance collaborations, and scale opportunities with addiction centers and managed care organizations.

Technology Leverage Titan’s ProNeura platform and tech stack readiness indicate potential for standalone licensing or joint development with device-integrated drug delivery players, neurotherapeutics, or endocrinology products requiring steady-state pharmacokinetics.

Funding Readiness With $56M in funding and a small, agile team, there is appetite for strategic collaborations, milestone-driven partnerships, and co-funding of late-stage development or commercialization efforts to accelerate growth while managing risk.